IP Library Granted Patent US 8,455,227
Granted Patent B2
US 8,455,227 · App. 11/922,404 · Granted Jun 4, 2013

Detection of HIV-1 infection

Inventors: Tomasz Rozmyslowicz (Deptford, NJ); Krzysztof Wroblewski (Broomall, PA); Glen N. Gaulton (Havertown, PA)
Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,455,227
App. No.
11/922,404
Granted
Jun 4, 2013
Kind
B2
Abstract

This invention provides methods for to the use of the difference in phosphodiester (PDE)/phosphomonoester (PME) ratio in biological fluids, as an analytical criterion to image both the presence and degree of viral infection in-vivo.

Claims (10)

1. A method for monitoring the severity of human immunodeficiency virus (HIV) infection in a subject, comprising:

(1) obtaining a biological sample comprising lymphocytes from said subject;

(2) measuring the concentration of phosphodiester (PDE) and the concentration of phosphomonoester (PME) in said biological sample;

(3) computing an observed ratio of phosphodiester (PDE)/phosphomonoester (PME) from said concentrations;

(4) comparing said observed ratio with a standard ratio obtained from the biological sample of a non-infected control subject; and

(5) computing the difference between said observed ratio and standard ratio, wherein, the larger the difference between the observed ratio and the standard ratio, the more severe is the infection.

2. The method of claim 1 , wherein said biological sample is plasma, saliva, urine, blood cell, lymphatic fluids, peripheral blood mononuclear cells (PBMC), thymocytes, or a combination thereof.

3. The method of claim 1 , wherein said step of measuring the concentrations of PDE and PME comprises magnetic resonance imaging (MRI), nuclear magnetic resonance (NMR), high performance liquid chromatography (HPLC), gas chromatography(GC), mass spectrometry (MS), or a combination thereof.

4. The method of claim 1 , wherein the HIV is HIV-1.

5. The method of claim 1 , wherein said standard ratio is about 0.482 as measured by NMR of perchloric acid extracts from thymocytes.

Assignments (3)
CONFIRMATORY LICENSE Recorded Mar 2, 2010
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024009/0942 →
CONFIRMATORY LICENSE Recorded Mar 2, 2010
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024009/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2008
From: ROZMYSLOWICZ, TOMASZ; WROBLEWSKI, KRZYSZTOF; GAULTON, GLEN N.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 021560/0600 →
Continuity (3)
Provisional Application 60690489 · Jun 15, 2005
Provisional Application 60690491 · Jun 15, 2005
Related Publication 20100034747A1 · Feb 11, 2010